GLP1R and obesity due to melanocortin 4 receptor deficiency: Here, we describe the discovery and characterization of BI 456906, a once-weekly, injectable GCGR/GLP-1R dual agonist currently in Phase II clinical development for obesity, type 2 diabetes, and NASH.